bioRxiv Science⌕ Search

bioRxiv · 10.1101/2023.06.16.545225

Epitope spreading of Lyme autoantigen apoB-100 and CD4+ T cell responses to Borrelia burgdorferi Mcp4 are regulated by IL-10 in murine Lyme disease

Abstract

Borrelia burgdorferi, the causative agent of Lyme disease (LD), has evolved immune evasion mechanisms to establish a persistent infection in their vertebrate hosts, resulting in chronic inflammation and autoimmune T and B cell reactivity in many B. burgdorferi-infected individuals. In this study, we used an unbiased immunopeptidomics approach to identify foreign and self MHC class II peptides isolated from inguinal and popliteal lymph nodes from B. burgdorferi- infected C57BL/6 (B6) mice, which develop mild, self-limiting LD; and from infected B6 Il10-/- mice, which develop severe, persistent LD. Nearly 10,000 MHC-II peptides were identified by LC-tandem MS analysis which included many peptides derived from proteins abundant in arthritic joints that are associated with inflammation, tissue repair, and extracellular matrix remodeling. Notably, the number and variety of unique peptides derived from apolipoprotein B- 100 (apoB-100); a validated autoantigen in human Lyme arthritis (LA), atherosclerosis, and liver disease; was greatly expanded in lymph nodes of infected mice, particularly in Il10-/- mice at 4 weeks (6-fold increase) and 16 weeks (15-fold increase) post-infection, compared with uninfected mice, indicating epitope spreading. One of the apoB-100 peptides identified in infected, but not uninfected, B6 and Il10-/- mice was APOB3500-3515, an immunogenic cryptic epitope in murine autoimmune atherosclerosis. No apoB-100 peptides had sequence homology to any B. burgdorferi antigens. Surprisingly, only six peptides derived from B. burgdorferi proteins were validated in this study. One of these B. burgdorferi epitopes, derived from methyl- accepting chemotaxis protein Mcp4 (BB0680), was an immunogenic target of CD4+ T cell responses in B. burgdorferi-infected Il10-/- mice, but not in B6 mice. In conclusion, this study has shed light on the importance of IL-10 in suppressing epitope spreading and limiting B. burgdorferi-specific CD4+ T cell responses. Furthermore, this study supports epitope spreading and exposure of cryptic antigens as likely mechanisms of infection-induced apoB-100 autoimmunity in LD. AUTHOR SUMMARYLyme disease is caused by infection with the spirochetal pathogen Borrelia burgdorferi, and affects [~]500,000 individuals in the U.S. annually. T cell responses to both host and pathogen are dysregulated during infection, resulting in chronic infection and frequent development of autoimmunity. To assess the immune-relevant CD4+ T cell epitopes presented during development of Lyme disease, we used an unbiased, immunopeptidomics approach to characterized the MHC class II immunopeptidome in mice infected with Borrelia burgdorferi. We identified nearly 10,000 unique peptides. Peptides derived from apoB-100, a known human Lyme autoantigen, were highly enriched in infected mice, compared with uninfected controls, and showed evidence of epitope spreading. Furthermore, we identified several peptides derived from Borrelia burgdorferi, including one immunogenic peptide from a methyl-accepting chemotaxis protein, Mcp4. Interestingly, both apoB-100 epitope spreading and immune responses to Mcp4 were observed in mice lacking the anti-inflammatory cytokine IL-10, indicating an important role of IL-10 in suppressing T cell responses to Mcp4 and epitope spreading of Lyme autoantigen apoB-100.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Danner, R., Pereckas, M., Rouse, J. R., Wahhab, A., Prochniak, L. M., Lochhead, R. B.. 2023-06-18. Epitope spreading of Lyme autoantigen apoB-100 and CD4+ T cell responses to Borrelia burgdorferi Mcp4 are regulated by IL-10 in murine Lyme disease. https://doi.org/10.1101/2023.06.16.545225

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

CTR1-mediated copper uptake orchestrates metabolic-epigenetic regulation of pathogenic TH17 cells in autoimmune disease

Pathogenic T helper 17 (pTH17) cells are a subset of CD4+ T cells driving autoimmune diseases including multiple sclerosis (MS). Compared to homeostatic TH17 cells and other TH subsets, pTH17 have enhanced mitochondrial function and oxidative phosphorylation (OXPHOS) that supports their differentiation and pathogenic function. Here we identify Copper Transporter 1 (CTR1), encoded by Slc31a1, as essential for copper uptake in CD4+ T cells, OXPHOS and pTH17 cell differentiation and function. While copper levels are known to be higher in the cerebrospinal fluid of patients with MS compared to healthy individuals, and excess copper contributes to oligodendrocyte loss in murine models of MS, the effect of copper on T cell function and pathogenicity in MS are unclear. We demonstrate that deletion of Slc31a1 in CD4+ T cells decreased intracellular copper levels, disrupting mitochondrial respiration and rewiring metabolism. These changes altered the epigenetic landscape of pTH17 cells by impairing DNA demethylation capacity, leading to hypermethylated DNA and altered chromatin accessibility at key binding sites for AP-1 transcription factors essential for pTH17 differentiation. As a result, CTR1-deficient T cells showed defective differentiation into pTH17 cells, with decreased production of IL-17A and expression of TH17 signature genes, while the differentiation of other CD4+ T cell subsets remained largely unaffected. Moreover, T cell-specific deletion of Slc31a1 protected mice from central nervous system (CNS) inflammation in the experimental autoimmune encephalomyelitis (EAE) model of MS by suppressing clonal expansion of autoreactive CD4+ T cells. These findings establish copper as a critical regulator of pTH17 differentiation and function, revealing a previously unknown molecular link between copper homeostasis, metabolism and epigenetic regulation governing pTH17-mediated autoimmunity.

immunology↗

Fetal-intrinsic antiviral mechanisms emerge over the course of gestation

Congenital viral infections have variable effects on pregnancy outcomes with implications for maternal and fetal health. However, the maternal and fetal immune mechanisms that emerge over the course of gestation to determine protective or pathological outcomes remain poorly understood. Here, we use the emerging congenital pathogen Oropouche virus (OROV) to examine gestational stage-dependent differences in maternal and fetal outcomes in a mouse model of congenital infection. Pregnant mice (dams) infected during early gestation resist severe OROV disease, whereas mid-gestation-infected dams succumb to infection. In contrast, fetal pathology is substantial following early gestation infection but limited following infection during mid-gestation, revealing discordant maternal and fetal susceptibility across gestation. Mid-gestation fetal tissues effectively restricted vertical transmission compared to early gestation fetal tissues, corresponding with reduced fetal pathology. Moreover, both placental and fetal tissue cleared OROV RNA over the course of infection, independent of gestational stage, and failure to clear viral RNA was associated with severe fetal pathology. Spatial analysis of early gestation implantation sites further revealed distinct regional susceptibility to OROV infection across the maternal-fetal interface. We identified potential instances of placental-independent vertical transmission via direct fetal contact with highly infected regions of the contralateral maternal uterus. Finally, we uncovered an unexpected mechanism by which type I interferon signaling contributes to inter-fetal immune crosstalk to restrict both OROV vertical transmission and pathology. Together, these findings establish the fetus as an active participant in antiviral defense and reveal previously unrecognized mechanisms by which fetal-intrinsic antiviral immune responses limit congenital viral infection and disease.

immunology↗

Interferon lambda drives immunological maturation in the infant lung and protects against lethal Bordetella pertussis infection

Serious pertussis infections disproportionately affect infants but the biological basis for this age-dependent susceptibility remains unclear. Infant mouse models recapitulate features of severe human infant pertussis. We investigated the role of interferon lambda (IFN-{lambda}), a key regulator of mucosal immunity, in Bordetella pertussis infection of infant mice. While infected adult mice upregulate lung IFN-{lambda}, infant mice inoculated at P7 fail to upregulate IFN-{lambda} and succumb to infection. We hypothesized that failure to produce IFN-{lambda} during infection represents a critical immunological deficit in infant mice, and that restoring IFN-{lambda} signaling would improve survival outcomes. Whereas wild-type mice gained complete protection from lethal B. pertussis infection by P10, mice lacking the IFN-{lambda} receptor component IFNLR1 did not achieve full protection until P21. Loss of IFNLR1 was associated with enhanced bacterial dissemination to systemic organs. Infant mice possessed a functional IFN-{lambda} receptor in the lungs but failed to upregulate IFN-{lambda} during infection, and supplementing IFN-{lambda} exogenously extended survival. RNA sequencing of lung tissue from infected and uninfected wild-type and IFNLR1-deficient mice inoculated at different ages identified an immune transcriptional framework distinguishing susceptible from resistant animals at a systems level and revealed IFN-{lambda} signaling as a critical driver of immunological maturation in the infant lung. Infected infant IFNLR1-deficient mice had dysregulated immune cell recruitment to the lungs, indicating a quantitatively expanded but qualitatively impaired response. These findings demonstrate that IFN-{lambda} affects immune maturation accounting for a critical window of age-dependent resistance to lethal pertussis with novel therapeutic possibilities for human infants with this disease.

immunology↗